Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000729362 | SCV000252002 | uncertain significance | not provided | 2014-04-22 | criteria provided, single submitter | clinical testing | p.Asp351Gly (GAT>GGT): c.1052 A>G in exon 9 of the PDHX gene (NM_003477.2) The D351G variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. The D315G variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. The variant is found in MITONUC-MITOP panel(s). |
Eurofins Ntd Llc |
RCV000729362 | SCV000857017 | uncertain significance | not provided | 2017-09-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000729362 | SCV002225026 | likely benign | not provided | 2024-03-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV005384672 | SCV006044694 | uncertain significance | Inborn genetic diseases | 2025-02-07 | criteria provided, single submitter | clinical testing | The c.2564T>G (p.L855R) alteration is located in exon 25 (coding exon 25) of the OPA1 gene. This alteration results from a T to G substitution at nucleotide position 2564, causing the leucine (L) at amino acid position 855 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |